The information contained at this site is technical in nature
and was specifically created for US Health Care Professionals.
Learn about Alzheimer's,
its underlying neuropathology,
and the role of Amyvid
Learn the key anatomy, steps,
and interpretation criteria for
Amyvid PET images
Put your knowledge
to the test with real
INDICATIONS AND USAGE
Amyvid is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate beta-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease (AD) and other causes of cognitive decline.
A negative Amyvid scan indicates sparse to no neuritic plaques and is inconsistent with a neuropathological diagnosis of AD at the time of image acquisition; a negative scan result reduces the likelihood that a patient's cognitive impairment is due to AD. A positive Amyvid scan indicates moderate to frequent amyloid neuritic plaques; neuropathological examination has shown this amount of amyloid neuritic plaque is present in patients with AD, but may also be present in patients with other types of neurologic conditions as well as older people with normal cognition. Amyvid is an adjunct to other diagnostic evaluations.
Limitations of Use:
Amyvid for intravenous use is supplied in 10 mL, 30 mL, or 50 mL multidose vials containing 500-1900 MBq/mL Florbetapir F 18.
IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
Risk for Image Misinterpretation and Other Errors
MOST COMMON ADVERSE REACTIONS
AM HCP ISI 10JAN2014